This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horwitz, K. B. Articles by Freidenberg, G. R. Search for Related Content PubMed PubMed Citation Articles by Horwitz, K. B. Articles by Freidenberg, G. R.

Growth Inhibition and Increase of Insulin Receptors in Antiestrogen-resistant T47D_co Human Breast Cancer Cells by Progestins: Implications for Endocrine Therapies¹

Department of Medicine and Biochemistry, Biophysics, and Genetics, University of Colorado Health Sciences Center, Denver, Colorado 80262

There is renewed interest in the use of progestins to treat advanced breast cancer because results with these agents are comparable to those obtained with antiestrogens. However, it is not known whether progestins inhibit the growth of breast tumor cells directly and independently of estradiol. To study this, we have used T47D_co human breast cancer cells. The progesterone receptors in these cells do not require estrogen induction, and this permits study of pure progestin effects without interference by estradiol. We report here that, in the absence of estradiol, physiological concentrations of progestins directly inhibit proliferation of these cells. At the same time, progestins increase the levels of the receptors for insulin, a common cell mitogen. Ten days of treatment with 1 or 10 nM of the synthetic progestin R5020 suppresses cell growth approximately 50 to 60%. This is consistent with the concentrations that either partially (approximately 10%) or more extensively (>60%) translocate cytoplasmic progesterone receptors. Even a brief 1-hr pulse of R5020 has long-term growth-inhibitory effects. Progesterone is also antiproliferative, but its effects are attenuated because, unlike R5020, it is rapidly metabolized in the medium. Other synthetic progestins also inhibit cell growth, but unrelated steroids (estradiol, androgens, glucocorticoids, 1,25-dihydroxyvitamin D₃) are ineffective. While growth is suppressed by R5020, insulin receptors increase rapidly and then fall to a new, elevated steady state as the cells slowly begin to proliferate. Only progestins have this effect on insulin receptors. We conclude that the hormonal regulation of breast tumor cell growth is complex and includes progestins among the regulating factors. Furthermore, since T47D_co cells are antiestrogen-resistant and estrogen receptor-negative, the antiproliferative effects of progestins must be mediated through mechanisms that differ from the cytotoxic effects of antiestrogens. We propose that, clinically, antiestrogens and progestins may have complementary uses in breast cancer treatment, and we outline two therapeutic strategies.

¹ This work was supported by Grant CA-26869 from the NIH.

² Recipient of Research Career Development Award CA-00694 from the NIH. To whom requests for reprints should be addressed.

³ Present address: Department of Medicine, University of California at San Diego, La Jolla, CA 92093.

Received 4/ 2/84. Accepted 9/27/84.

This article has been cited by other articles:

				J. E Morabito, J. F Trott, D. M Korz, H. E Fairfield, S. H Buck, and R. C Hovey A 5' distal palindrome within the mouse mammary tumor virus-long terminal repeat recruits a mammary gland-specific complex and is required for a synergistic response to progesterone plus prolactin J. Mol. Endocrinol., August 1, 2008; 41(2): 75 - 90. [Abstract] [Full Text] [PDF]

				A. Chadli, J. D. Graham, M. G. Abel, T. A. Jackson, D. F. Gordon, W. M. Wood, S. J. Felts, K. B. Horwitz, and D. Toft GCUNC-45 Is a Novel Regulator for the Progesterone Receptor/hsp90 Chaperoning Pathway. Mol. Cell. Biol., March 1, 2006; 26(5): 1722 - 1730. [Abstract] [Full Text] [PDF]

				T. Suzuki, A. D. Darnel, J.-I. Akahira, N. Ariga, S. Ogawa, C. Kaneko, J. Takeyama, T. Moriya, and H. Sasano 5{{alpha}}-Reductases in Human Breast Carcinoma: Possible Modulator of in Situ Androgenic Actions J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2250 - 2257. [Abstract] [Full Text]

				A. Swarbrick, C. S. L. Lee, R. L. Sutherland, and E. A. Musgrove Cooperation of p27Kip1 and p18INK4c in Progestin-Mediated Cell Cycle Arrest in T-47D Breast Cancer Cells Mol. Cell. Biol., April 1, 2000; 20(7): 2581 - 2591. [Abstract] [Full Text]

				C. A. Lange, J. K. Richer, and K. B. Horwitz Hypothesis: Progesterone Primes Breast Cancer Cells for Cross-Talk with Proliferative or Antiproliferative Signals Mol. Endocrinol., June 1, 1999; 13(6): 829 - 836. [Full Text]

				E. A. Musgrove, A. Swarbrick, C. S. L. Lee, A. L. Cornish, and R. L. Sutherland Mechanisms of Cyclin-Dependent Kinase Inactivation by Progestins Mol. Cell. Biol., April 1, 1998; 18(4): 1812 - 1825. [Abstract] [Full Text]

				J. D. Graham and C. L. Clarke Physiological Action of Progesterone in Target Tissues Endocr. Rev., August 1, 1997; 18(4): 502 - 519. [Abstract] [Full Text] [PDF]